Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vorapaxar - Merck & Co/Old API Wind-down

Drug Profile

Vorapaxar - Merck & Co/Old API Wind-down

Alternative Names: MK-5348; SCH-530348; TRA; TRA-SCH-530348; Vorapaxar sulfate; Zontivity

Latest Information Update: 12 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Duke Clinical Research Institute; Kirby Institute for infection and immunity in society; Merck & Co; Old API Wind-down Ltd
  • Class 3-ring heterocyclic compounds; Antithrombotics; Carbamates; Cardiovascular therapies; Lactones; Pyridines
  • Mechanism of Action PAR 1 receptor antagonists; Thrombin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial thrombosis
  • Phase I/II Blood coagulation disorders; Inflammation
  • No development reported Cerebral infarction

Most Recent Events

  • 06 Feb 2019 Aralez Pharmaceuticals is now called Old API Wind-down
  • 24 Jun 2018 Biomarkers information updated
  • 04 Apr 2018 Vorapaxar is not yet launched for Arterial thrombosis (Prevention) in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top